|
Jul 17, 2023
|
PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
SOUTH PLAINFIELD, N.J. , July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist
|
|
|
Jul 11, 2023
|
PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
SOUTH PLAINFIELD, N.J. , July 11, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT), announced today that the company will provide a virtual presentation on PKU including discussion of the current therapeutic and commercial landscape with an expert key opinion leader.
|
|
|
Jun 29, 2023
|
PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
SOUTH PLAINFIELD, N.J. , June 29, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the MIT-E trial of vatiquinone for the treatment of mitochondrial disease associated seizures (MDAS) failed to achieve its primary endpoint of reduction in observable motor seizures.
|
|
|
Jun 21, 2023
|
PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
- D ose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks - - Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes - - Conference call and webcast to be held June 21 st at 8:00 am EDT - SOUTH PLAINFIELD, N.J.
|
|
|
Jun 15, 2023
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , June 15, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on June 12, 2023 , the company approved non-statutory stock options to purchase an aggregate of 11,260 shares of its common stock and 17,660 restricted stock units ("RSUs"), each
|
|
|
Jun 02, 2023
|
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , June 2, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Jefferies Healthcare Conference Wednesday, June 7 at 12:30 p.m.
|
|
|
May 23, 2023
|
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
- Conference call and webcast to be held at 5:00 pm EDT - SOUTH PLAINFIELD, N.J. , May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia.
|
|
|
May 23, 2023
|
PTC Therapeutics Announces Strategic Pipeline Prioritization
- Preclinical and early research gene therapy programs discontinued - - Expected reductions of approximately 15% in residual 2023 OPEX - SOUTH PLAINFIELD, N.J. , May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research
|
|
|
May 17, 2023
|
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
- Highly statistically significant and clinically meaningful results - - 63% mean blood Phe reduction in primary analysis population (p
|
|
|
Apr 28, 2023
|
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , April 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 24, 2023 , the company approved non-statutory stock options to purchase an aggregate of 10,770 shares of its common stock and 18,110 restricted stock units (RSUs), each
|
|
